Bernard J. Zovighian - May 30, 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 30, 2025
Transactions value $
-$1,317,837
Form type
4
Date filed
6/3/2025, 05:15 PM
Previous filing
May 16, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zovighian Bernard J CEO, Director ONE EDWARDS WAY, IRVINE Linda J. Park, Attorney-in-Fact 2025-06-03 0001665141

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Sale -$1.24M -16.1K -62.73% $77.21 9.56K May 30, 2025 By Trust F1, F2
transaction EW Common Stock Sale -$74.8K -967 -10.11% $77.32 8.6K Jun 3, 2025 By Trust F1, F3
holding EW Common Stock 81K May 30, 2025 Direct
holding EW Common Stock 3.61K May 30, 2025 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $76.930 to $77.585 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $77.140 to $77.540 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.